Pharming Group (NASDAQ:PHAR) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totalling 15,000 shares, a growth of 200.0% from the December 15th total of 5,000 shares. Based on an average trading volume of 9,800 shares, the days-to-cover ratio is presently 1.5 days.
An institutional investor recently raised its position in Pharming Group stock. Morgan Stanley increased its holdings in shares of Pharming Group (NASDAQ:PHAR) by 5,208.3% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,548 shares of the company’s stock after purchasing an additional 2,500 shares during the quarter. Morgan Stanley’s holdings in Pharming Group were worth $29,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 0.04% of the company’s stock.
Pharming Group stock opened at $9.26 on Friday. The company has a debt-to-equity ratio of 0.73, a current ratio of 5.18 and a quick ratio of 4.65. The business’s fifty day simple moving average is $8.66 and its two-hundred day simple moving average is $9.76. Pharming Group has a 12 month low of $7.58 and a 12 month high of $15.14.
About Pharming Group
Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema.
See Also: LIBOR
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.